Shigella Vaccines Market Global Outlook 2018-2026 Growth Rate and Forecast Assessment with Top key players MSD Wellcome Trust Hilleman Laboratories Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc.

Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are encompassed, such as S. dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that are the polysaccharides moiety of the lipopolysaccharide, a virulence factor consist of toxic lipid. According to the Centers for Disease Control and Prevention (CDC), in 2013, the average annual incidence of shigellosis in the U.S. was around 5 cases per 100,000 individuals. Bacillary dysentery with brutal epidemics are caused by S. dysenteriae by the production of shiga toxins whereas, the endemic form of disease is caused by the S. flexneri and S. sonnei. The bacillary dysentery is accompanied with fever, rectal inflammation, and abdominal cramps.

Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1110

According to World Health Organization (WHO), nearly one million people die from Shigella infection annually. Moreover, the high incidence rate is seen among children less than five years age, travelers, and military personnel from industrialized economies. Shigella species have been identified from centuries and it represents a major threat to public health, due to non-availability of licensed vaccine and thus affecting overall Shigella vaccines market.

Developing vaccine against Shigella infections is difficult, due to the diversity of Shigella species and their serotypes. Shigella genome is continuously modified by deletion and acquisition of genes mediated by the mobile genetic elements, such as plasmids, insertion sequences, and integrons. These modifications are the major foundation for the generation of novel antibiotic resistant strains and it also leads to the formation of novel Shigella serotype variants. Centers for Disease Control and Prevention (CDC) in April 2017, warned the physicians and public health officials in the U.S. by stating that the recent strains of Shigella bacteria shows the reduced susceptibility to ciprofloxacin, which is one of the main antibiotics recommended by WHO for the treatment of shigellosis.

Geographically, S. flexneri is the most frequent species occurred worldwide accounting for most cases in emerging economies. Whereas, the S. sonnei is prevalent in Brazil, China, Vietnam, and Bangladesh, due to rapid industrialization of these economies. The primary prevention of Shigella is based on the universal provision of portable sanitation and water methods along with personal and food hygiene. However, a low cost and effective vaccine would accelerate disease reduction across the globe.

Joint ventures and collaborations of major players to develop and commercializes the vaccine are expected to propel the Shigella vaccines market in near future

Joint ventures and partnership of the players to develop and commercialize Shigella vaccine is expected to provide momentum to the Shigella vaccines market. For instance, in March 2017, Hilleman Laboratories, a non-profit organization established with joint venture partnership between Merck & Co., and Wellcome Trust has entered into an agreement with National Institute of Cholera and Enteric Disease (NICED) for the development and commercialization of vaccines against Shigella by 2024. Besides, in June 2016, Immuron- an Australian biopharmaceutical company entered into an agreement to produce Shigella vaccine with the U.S Army’s biomedical research lab-Walter Reed Army Institute of Research (WRAIR).

Prokarium and Probiomed in January 2017, collaborated to manufacture orally-administrated vaccine to prevent diarrhea. The new vaccine is expected to be manufactured as a part of two-year collaboration having thermostable capabilities for a longer period. The new vaccine is expected to be delivered to the people living in the remote areas. Thermostable vaccine, which is manufactured approximately one third of the price of the conventional injectable vaccines helps to facilities the growth of Shigella vaccines market.

The new research trial drives the Shigella vaccines market

The University Of Maryland School Of Medicine (UM SOM) in August 2017 received US$ 2.47 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop vaccine against Shigella and Enterotoxigenic Escherichia coli (ETEC) for the treatment of diarrheal disease. The researchers in the UM SOM’s Center for Vaccine Development (CVD) have developed Shigella-ETEC prototype vaccine, which has been tested in animals successfully. Moreover, the latest funding helps to translate prototype to a human vaccine for Phase 1 clinical trials.

Buy This Research Report @
https://www.coherentmarketinsights.com/insight/buy-now/1110

The key players present in the global shigella vaccines market include MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.